Skip to Content

Enfortumab vedotin sets new standard for 3rd line treatment of advanced bladder cancer

The antibody drug-conjugate enfortumab vedotin significantly prolongs survival compared to standard chemotherapy in patients with locally advanced or metastatic urothelial carcinoma who have previously received platinum-based treatment and a PD-1 or PD-L1 inhibitor.

Avaa artikkeli

Jos olet lääkäri, sairaanhoitaja tai muu terveydenhuollon ammattilainen, voit käyttää koko artikkelia luomalla profiilin BestPractice Nordic -sivustolle.

Back to top